- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
EC approves two new indications for Lilly’s ramucirumab
28 January 2016 • Author: Victoria White
The European Commission has approved two new indications for Lilly’s Cyramza (ramucirumab).
The first indication is in combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression after platinum-based chemotherapy. This makes ramucirumab the first approved NSCLC therapy in the EU specifically indicated for use with docetaxel after prior chemotherapy, regardless of history.
The second indication is for ramucirumab in combination with Folfiri (irinotecan, folinic acid and 5 flourouracil) for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a flouropyrimidine.
Commenting on the announcement, Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology, said: “Lung and colorectal cancer are the two top leading causes of cancer deaths in the EU and, despite treatment advances, there continues to be a significant need for new second-line treatment options for people with these types of cancer. We are pleased to offer ramucirumab as a new option in these treatment settings as we continue delivering on Lilly’s commitment to people living with lung and gastrointestinal cancers.
Ramucirumab is an antiangiogenic therapy. It is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that specifically binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics